IVERIC bio (IVERIC bio) Days Payable : 0.00 (As of Mar. 2023)

View and export this data going back to 2013. Start your Free Trial

What is IVERIC bio Days Payable?

IVERIC bio's average Accounts Payable for the three months ended in Mar. 2023 was $20.43 Mil. IVERIC bio's Cost of Goods Sold for the three months ended in Mar. 2023 was $0.00 Mil.

The historical rank and industry rank for IVERIC bio's Days Payable or its related term are showing as below:

ISEE's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 146.16
* Ranked among companies with meaningful Days Payable only.

IVERIC bio's Days Payable stayed the same from Mar. 2022 (0.00) to Mar. 2023 (0.00). stayed the same

IVERIC bio Days Payable Historical Data

The historical data trend for IVERIC bio's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IVERIC bio Days Payable Chart

IVERIC bio Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Payable

Get a 7-Day Free Trial

IVERIC bio Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of IVERIC bio's Days Payable

For the Biotechnology subindustry, IVERIC bio's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IVERIC bio's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IVERIC bio's Days Payable distribution charts can be found below:

* The bar in red indicates where IVERIC bio's Days Payable falls into.

IVERIC bio Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

IVERIC bio's Days Payable for the fiscal year that ended in Dec. 2022 is calculated as

	Days Payable (A: Dec. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2021 )	+	Accounts Payable (A: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2022 )	*	Days in Period
=	( (12.856	+	22.843)	/	2 )	/	0	*	365
=	17.8495					/	0	*	365
=	N/A

IVERIC bio's Days Payable for the quarter that ended in Mar. 2023 is calculated as:

	Days Payable (Q: Mar. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2022 )	+	Accounts Payable (Q: Mar. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2023 )	*	Days in Period
=	( (22.843	+	18.026)	/	2 )	/	0	*	365 / 4
=	20.4345					/	0	*	365 / 4
=	N/A

IVERIC bio Days Payable Related Terms

Thank you for viewing the detailed overview of IVERIC bio's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

IVERIC bio (IVERIC bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IVERIC bio Inc (NAS:ISEE) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 Sylvan Way, Parsippany, New Jersey, USA, 07054

Website

https://www.ivericbio.com

IVERIC bio Inc is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases, or IRDs.

Executives

Keith Westby	officer: SVP & COO	ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540
David Francis Carroll	officer: SVP, CFO and Treasurer	ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540
Glenn Sblendorio	director	3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
Christopher Paul Simms	officer: Senior Vice President, CCO	FIVE PENN PLAZA SUITE 2372, NEW YORK NY 10001
Anthony S Gibney	officer: EVP, Chief Business Officer	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Calvin W. Roberts	director	6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Christine Ann Miller	director	5 PENN PLAZA, SUITE 2372, NEW YORK NY 10001
Pravin Dugel	officer: EVP, Chief Strategy & Business	C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, CINCINNATI OH 45242
David R Guyer	director, officer: Chief Executive Officer	ONE PENN PLAZA, 19TH FLOOR, NEW YORK NY 10119
Mark S. Blumenkranz	director	C/O 1LIFE HEALTHCARE, INC., ONE EMBARCADERO CENTER, SUITE 1900, SAN FRANCISCO CA 94111
Adrienne L Graves	director	125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Versant Venture Capital Iv, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Iv, Llc	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Side Fund Iv, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Jane Henderson	director	C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142